振東製藥(300158.SZ):擬使用額度不超3億元自有資金進行現金管理
格隆匯8月17日丨振東製藥(300158.SZ)公佈,公司於2021年8月17日召開了第五屆董事會第一次會議,審議通過了《關於公司及其子公司使用自有資金進行現金管理的議案》。本着對股東利益最大化原則,為提高資金的使用效率,在確保不影響公司正常經營以及保證流動性和資金安全的前提下,同意公司及公司子公司使用額度不超過人民幣3億元的自有資金進行現金管理,並授權管理層在上述額度內負責辦理實施,授權期限自公司第五屆董事會第一次會議審議通過之日起一年。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.